These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15661048)

  • 1. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study.
    Takahashi N; Kawaguchi T; Suzuki T
    Int J Urol; 2005 Jan; 12(1):7-11. PubMed ID: 15661048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases.
    Ueda H; Shibahara N; Takagi S; Inoue T; Katsuoka Y
    Ther Apher Dial; 2007 Jun; 11(3):189-95. PubMed ID: 17498000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
    Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
    J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
    Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
    Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure.
    Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Shimada N; Ebihara I; Koide H
    Kidney Blood Press Res; 2004; 27(2):121-6. PubMed ID: 15051932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
    Sanaka T; Akizawa T; Koide K; Koshikawa S
    Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estimating the cost savings due to the effect of Kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure].
    Kang HY; Cho W; Lee S; Kim HJ; Lee HY; Woo TW
    J Prev Med Public Health; 2006 Mar; 39(2):149-58. PubMed ID: 16615270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
    Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
    Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of angiotensin II receptor antagonist (losartan) on renal function, serum potassium and blood pressure in patients with advanced renal failure: differences between patients with a serum creatinine (SCr) level higher than 3 mg/dl and those with a lower SCr level].
    Nakayama M; Tanno Y; Otsuka Y; Takahashi H; Ikeda M; Katoh N; Yokoyama K; Yamamoto H; Tokutome G; Hosoya T
    Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):530-6. PubMed ID: 12476589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the initiation time of drug treatment for chronic renal failure].
    Takahashi S; Okada K
    Nihon Jinzo Gakkai Shi; 1993 Jun; 35(6):765-76. PubMed ID: 8377290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
    Schulman G; Agarwal R; Acharya M; Berl T; Blumenthal S; Kopyt N
    Am J Kidney Dis; 2006 Apr; 47(4):565-77. PubMed ID: 16564934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonic adsorbent AST-120 retards progression of renal failure by additive effect with ACEI and protein restriction diet.
    Imai E; Takenaka M; Isaka Y; Moriyama T; Akagi Y; Kakuchi J; Fujii T; Ito T; Hori M; Horio M; Syoji T; Tsubakihara Y
    Clin Exp Nephrol; 2003 Jun; 7(2):113-9. PubMed ID: 14586729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of laparoscopic radical and partial nephrectomy: effects on long-term serum creatinine.
    Zorn KC; Gong EM; Orvieto MA; Gofrit ON; Mikhail AA; Msezane LP; Shalhav AL
    Urology; 2007 Jun; 69(6):1035-40. PubMed ID: 17572181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
    Akizawa T; Asano Y; Morita S; Wakita T; Onishi Y; Fukuhara S; Gejyo F; Matsuo S; Yorioka N; Kurokawa K;
    Am J Kidney Dis; 2009 Sep; 54(3):459-67. PubMed ID: 19615804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
    Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.